

STOP-ACEi advertising text

### **An invitation to join the STOP-ACEi trial**

#### **Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced renal disease; the STOP-ACEi trial.**

Chronic kidney disease (CKD) affects 1 in 10 people in the UK. Treating high blood pressure is the most important intervention that can slow progression of CKD. Some people with CKD gain additional protection from drugs called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs). However recent research suggests that in some people with CKD stage 4 or 5, that stopping these drugs can lead to a stabilisation and improvement of kidney function and decreases or delays the need for dialysis treatment. The trial will test whether stopping ACEi and/or ARBs in patients with CKD stage 4 or 5 does lead to the stabilisation of or improvement in kidney function over a 3 year follow-up period, provided good blood pressure control is maintained with other agents, compared to continuing ACEi and/or ARB.

The trial will recruit participants for 2 years and each participant will have trial visits occurring once every three months for three years. To enter the trial, participants must be aged 18 years or over, with chronic kidney disease stage 4 or 5 and be taking ACEi or ARB or a combination of both. The trial is supported by the UK Comprehensive Clinical Research Network, has been funded by the Efficacy and Mechanism Evaluation (EME) Programme (part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials) and is sponsored the Hull and East Yorkshire Hospitals NHS Trust.

We do very much hope that you would be interested in participating in STOP-ACEi if you meet the entry criteria. We require a total of 410 patients nationally and approximately 20 centres across the UK are taking part. For further information please see the STOP-ACEi website ([www.birmingham.ac.uk/stopacei](http://www.birmingham.ac.uk/stopacei)) for contact details and for a list of participating UK centres or email [stopacei@trials.bham.ac.uk](mailto:stopacei@trials.bham.ac.uk).

Yours faithfully

Prof Sunil Bhandari, Consultant Nephrologist/Honorary Clinical Professor, Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust, Tel: 01482 674566, Fax: 01482 674998 Email: [Sunil.bhandari@hey.nhs.uk](mailto:Sunil.bhandari@hey.nhs.uk).